Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: OPB 31121

First Posted Date: 2009-12-10

Last Posted Date: 2012-07-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01029509

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Clofarabine
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2009-12-03

Last Posted Date: 2018-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 63

Registration Number: NCT01025154

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study

Completed

Conditions: Advanced Cancers

Interventions: Behavioral: Questionnaire and Review Session

First Posted Date: 2009-12-02

Last Posted Date: 2013-06-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01024166

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: MDS
Leukemia
CML
AML

Interventions: Drug: Cytarabine
Drug: Fludarabine

First Posted Date: 2009-11-25

Last Posted Date: 2016-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 151

Registration Number: NCT01019317

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy-Induced Peripheral Neuropathy Survey

Withdrawn

Conditions: Chemotherapy-induced Peripheral Neuropathy
Colorectal Cancer
Breast Cancer
Myeloma

Interventions: Behavioral: Questionnaire
Behavioral: Sensory Tests
Behavioral: Interview

First Posted Date: 2009-11-18

Last Posted Date: 2016-05-03

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01016028

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Dasatinib
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2009-11-18

Last Posted Date: 2022-11-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 122

Registration Number: NCT01015222

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Physician Perceptions About Parenteral Hydration in Latin America and Spain

Conditions: Advanced Cancers
Dehydration

Interventions: Behavioral: Survey

First Posted Date: 2009-11-11

Last Posted Date: 2019-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 516

Registration Number: NCT01011140

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Phase 2

Completed

Conditions: Blood Stem Cell Transplant Failure
Leukemia
Hematologic Malignancies

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Melphalan
Drug: Mesna
Drug: Rituximab
Procedure: Stem Cell Transplantation
Drug: Thiotepa
Drug: Tacrolimus
Drug: Mycofenolate mofetil
Drug: G-CSF

First Posted Date: 2009-11-09

Last Posted Date: 2020-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 176

Registration Number: NCT01010217

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Determinants of Smoking Cessation Among Latinos

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Drug: Nicotine Replacement Therapy (NRT)
Behavioral: Questionnaire
Behavioral: Counseling
Behavioral: Self-Help Materials

First Posted Date: 2009-11-06

Last Posted Date: 2020-03-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT01008748

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Motivational Interviewing for Physical Activity

Not Applicable

Active, not recruiting

Conditions: Cancer

Interventions: Behavioral: Interview
Behavioral: Training
Behavioral: PA Newsletter
Behavioral: Questionnaire

First Posted Date: 2009-11-06

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT01008787

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy